Quarterly Updates14 May 2026, 05:21 pm
Venmax Drugs: FY26 Revenue at ₹802.49 Lakhs
AI Summary
Venmax Drugs and Pharmaceuticals Ltd announced audited financial results for the quarter and year ended March 31, 2026. Revenue from operations for FY26 stood at ₹802.49 lakhs, compared to ₹80.73 lakhs in FY25. The company reported a profit of ₹24.82 lakhs for the year, a significant improvement from a loss of ₹1.05 lakhs in the previous year. The Board Meeting was held on May 14, 2026, where the results were approved.
Key Highlights
- Revenue from operations for FY26 reached ₹802.49 lakhs, a substantial increase from ₹80.73 lakhs in FY25.
- The company achieved a profit of ₹24.82 lakhs for FY26, turning around from a loss of ₹1.05 lakhs in FY25.
- Earnings per Equity Share (Basic and Diluted) stood at ₹0.21 for FY26.
- The Board of Directors approved the audited standalone financial results on May 14, 2026.
- During the year, the company converted 63,44,000 share warrants into equity shares.